Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Slow wave activity as a marker of levodopa induced dyskinesia
Objective: To assess the role of slow wave activity during slow wave sleep (SWS-SWA) as a marker of levodopa induced dyskinesia (LID) development in Parkinson's…The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with bitopertin on dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD).…Ballistic single-joint arm movements in levodopa-induced dyskinesias in Parkinson´s disease.
Objective: To design a pilot study to analyze ballistic movements in Parkinson's disease patients with levodopa-induced dyskinesia. Background: Ballistic movements are characterized by an electromyographic…Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors
Objective: To characterize the patterns of cortico-basal ganglia oscillations induced by D1 or D2 receptor agonists in a rat model of L-DOPA-induced dyskinesia. Background: In…Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies
Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms including Sleep: Results from a Meta-Analysis with 24-month follow-up
Objective: To evaluate the impact of levodopa-carbidopa intestinal gel (LCIG) on dyskinesia, sleep, and other non-motor symptoms over 24 months after initiation. Background: Complications of…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on abnormal involuntary movements and parkinsonism in the 6-OHDA-lesioned rat
Objective: To assess the effect of LY-404,039 on dyskinesia and parkinsonism in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD). Background: LY-404,039 is an…Analysis of Sleep Structure and EEG Characteristics of Patients with Dyskinesia in Parkinson’s Disease
Objective: We aim to use objective polysomnography to analyze the relationship between dyskinesia and sleep structure in patients with Parkinson's disease. Background: Levodopa is an…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 40
- Next Page »